Judy Much

发表

Using the common sense model to understand perceived cancer risk in individuals testing for BRCA1/2 mutations

J. Dermody, D. Toppmeyer, M. Andrykowski, 2005, Psycho-oncology.

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies

D. Toppmeyer, C. Slapak, L. Green, 2002 .

Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.

Kimberly M. Kelly, J. Dermody, D. Toppmeyer, 2004, Genetic testing.

Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent

J. Dermody, D. Toppmeyer, H. Leventhal, 2003, Journal of Genetic Counseling.